A novel series of biphenyltetrazololactams has been identified as potent angiotensin receptor antagonists.These compounds were then evaluated in two in vivo preparations to determine their oral efficacy as antihypertensives.From these preparations RWJ 46458 (I), was identified as a lead compound and subjected to secondary evaluation.